JFG
LBRX

Jefferies Financial Group’s LB Pharmaceuticals LBRX Stock Holding History

Jefferies Financial Group’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,445
Closed -$277K – 2313
2025
Q4 		$277K Sell
12,445
-655
-5% -$11.4K ﹤0.01% 1519
2025
Q3 		$207K Buy
+13,100
New +$208K ﹤0.01% 1272

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Jefferies Financial Group's LBRX Position: Q1 2026 in Review

Jefferies Financial Group sold out of LB Pharmaceuticals (LBRX) in Q1 2026, closing a stake of 12,445 shares — an estimated $277K sold.

Jefferies Financial Group first reported a position in LBRX in Q3 2025 and held it in 2 quarters. The position peaked at $277K in Q4 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • Jefferies Financial Group reported no remaining LB Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 12,445 LB Pharmaceuticals shares in Q1 2026, an estimated $277K.
  • Jefferies Financial Group first reported a position in LB Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Jefferies Financial Group's LB Pharmaceuticals position peaked at $277K in Q4 2025.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.